Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caudal ketamine or midazolam added to bupivacaine to prevent emergence agitation in children
PACTR202111603969039Phase 2Recruiting
- Sponsor
- Mansoura University
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ketamine, midazolam and bupivacaine in Emergence agitation (EA) and postoperative pain (2 arms), sponsored by Mansoura University. Primary endpoint: Prevention of emergence agitation. Started Nov 2020; status: recruiting.
02
Drugs
ketaminemidazolambupivacaine
03
Conditions
Emergence agitation (EA)postoperative pain
Beyond the preview
Go deeper on PACTR202111603969039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202111603969039.